Core Insights - The company, Ying'en Biotech, announced plans to issue ordinary shares for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, subject to market conditions and necessary approvals [2] Company Overview - Ying'en Biotech focuses on developing next-generation antibody-drug conjugates (ADCs) for cancer and autoimmune disease patients, aiming to innovate cancer treatment methods [2] - The company was officially listed on the Hong Kong Stock Exchange on April 15, raising approximately HKD 1.64 billion (around USD 211 million) and attracting 15 cornerstone investors, marking the largest financing scale for a Hong Kong 18A listing since 2022 [2] Financial Performance - Projected revenues for Ying'en Biotech from 2022 to 2024 are as follows: CNY 1.6 million, CNY 1.787 billion, and CNY 1.941 billion, primarily from upfront payments and milestone revenues from products like DB-1303 and DB-1311 [2] - The net profit projections for the same period are: CNY -387 million, CNY -358 million, and CNY -1.05 billion [2] - In the first half of 2025, the company reported revenue of CNY 1.229 billion, a year-on-year increase of 22.9%, while net losses expanded to CNY -2.074 billion [2]
香港上市六个月后，知名药企映恩生物拟回A股上市